RxDoctor Payments Data

Jonathan Hoda, MD

Cardiovascular Disease · Hermitage, TNNPI 1053519785

Payments from drug & device makers

$12,946in general payments, 2019–2025

Across 561 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$3K
  • Amgen$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$933
  • Boehringer Ingelheim$866
  • Johnson & Johnson$831
  • Boston Scientific$829
  • plus $6K from 38 others

What the payments were for

  • Travel & lodging$1,84614%
  • Food & beverage$11,05985%
  • Education$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,946 in reported general payments places this provider in the 75th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$170,618
Medicare patients
1,292
Services billed
3,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$439,241
JardianceEmpagliflozin141$148,888
XareltoRivaroxaban128$135,661
MounjaroTirzepatide59$81,405
FarxigaDapagliflozin Propanediol93$80,982
Repatha SureclickEvolocumab44$43,141
OzempicSemaglutide22$28,026
RybelsusSemaglutide13$25,088
EntrestoSacubitril/Valsartan21$23,640
Rosuvastatin Calcium919$17,371
Praluent PenAlirocumab11$9,060
Ezetimibe177$7,101
ClopidogrelClopidogrel Bisulfate254$3,598
Prasugrel Hcl29$3,077
Carvedilol272$2,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$715$439,241342 claims
Boehringer IngelheimJardiance$866$148,888141 claims
Johnson & JohnsonXarelto$831$135,661128 claims
Lilly USA, LLCMounjaro$32$81,40559 claims
AstraZenecaFarxiga$367$80,98293 claims
Novo NordiskOzempic, Rybelsus$698$53,11435 claims
NovartisEntresto$375$23,64021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Hermitage

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →